Urogen Pharma (URGN) Raised to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of Urogen Pharma (NASDAQ:URGN) from a sell rating to a hold rating in a research note issued to investors on Saturday.
According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “
Several other research analysts also recently weighed in on the stock. Oppenheimer set a $75.00 target price on shares of Urogen Pharma and gave the stock a buy rating in a report on Tuesday, November 13th. Jefferies Financial Group assumed coverage on shares of Urogen Pharma in a report on Thursday, November 8th. They issued a buy rating and a $77.00 target price for the company. Stifel Nicolaus assumed coverage on shares of Urogen Pharma in a report on Thursday, September 13th. They issued a buy rating and a $70.00 target price for the company. Finally, Cowen reaffirmed a buy rating on shares of Urogen Pharma in a report on Tuesday, August 14th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Urogen Pharma presently has an average rating of Buy and an average price target of $71.75.
Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, November 15th. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.19). The firm had revenue of $0.28 million during the quarter. Urogen Pharma had a negative return on equity of 61.06% and a negative net margin of 4,296.08%. On average, analysts expect that Urogen Pharma will post -4.47 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in URGN. Menora Mivtachim Holdings LTD. boosted its holdings in shares of Urogen Pharma by 22.2% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 2,499,870 shares of the company’s stock valued at $124,394,000 after purchasing an additional 454,241 shares during the last quarter. Citadel Advisors LLC boosted its holdings in shares of Urogen Pharma by 294.6% during the 2nd quarter. Citadel Advisors LLC now owns 321,034 shares of the company’s stock valued at $15,974,000 after purchasing an additional 239,676 shares during the last quarter. Credit Suisse AG boosted its holdings in shares of Urogen Pharma by 53.1% during the 3rd quarter. Credit Suisse AG now owns 419,828 shares of the company’s stock valued at $19,828,000 after purchasing an additional 145,627 shares during the last quarter. BlackRock Inc. bought a new position in shares of Urogen Pharma during the 2nd quarter valued at about $4,468,000. Finally, Man Group plc boosted its holdings in shares of Urogen Pharma by 404.2% during the 3rd quarter. Man Group plc now owns 106,548 shares of the company’s stock valued at $5,033,000 after purchasing an additional 85,416 shares during the last quarter. 70.41% of the stock is owned by institutional investors and hedge funds.
About Urogen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Featured Article: What does cost of debt say about a company’s financial health?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.